Sanofi Acquires Vigil Neuroscience to Advance Alzheimer’s Treatment
On May 21, 2025, SanofiDealroom has a profile for this one. Try Dealroom → has announced the acquisition of Vigil Neuroscience, a clinical-stage biotech company focused on therapies for neurodegenerative diseases. The deal is valued at up to $600 million.
At the core of the acquisition is VG-3927, Vigil’s lead investigational therapy targeting TREM2, a protein essential for microglial activity in the brain. The oral small molecule aims to activate a protective immune response to slow or potentially alter the progression of Alzheimer’s disease. VG-3927 is expected to enter Phase 2 clinical trials soon.
Sanofi will pay $8 per share upfront, with an additional $2 per share tied to the commercial launch of VG-3927. The upfront payment amounts to approximately $470 million, with the total consideration reaching around $600 million.
The acquisition follows Sanofi’s $40 million equity investment in Vigil in June 2024, which included exclusive negotiation rights for VG-3927. The transaction strengthens Sanofi’s neurology pipeline and highlights its commitment to addressing Alzheimer’s.
The deal is anticipated to close in the third quarter of 2025, pending regulatory approval.
Sources:
A.M.
